GlobeNewsWire
27 Jul 2026, 16:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
FDA briefing documents for deramiocel concluded that data did not provide substantial evidence of effectiveness and noted the application relied on only one pivotal trial. — Directly undermines the likelihood of regulatory approval for the company's primary cell therapy candidate, leading to a massive loss in valuation.
-0.90Capricor Therapeutics shares fell more than 60% following the release of the FDA briefing documents. — Reflects immediate and severe market devaluation of the company's equity.
-0.70Law firm Block & Leviton is investigating Capricor Therapeutics for potential securities law violations regarding representations of the regulatory path for deramiocel. — Introduces significant legal risk and potential for costly class-action settlements on top of the drug failure.
-0.50Continue reading
6 related stories
Search tags
Reports indicate Capricor made multiple changes to its statistical analysis plan after the study was completed, raising concerns about data manipulation to generate a positive outcome. — Damages corporate credibility and suggests potential scientific misconduct, which may further alienate investors.
-0.40Which stocks this story touches
A securities fraud class action lawsuit has been filed against the company.
The company is being investigated for securities fraud following a 60% stock price drop and negative FDA briefing documents.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
